Can tumor necrosis factor inhibitors be safely used in pregnancy?

Journal of Rheumatology

Volumn 37, Issue 1, 2010, Pages 9-17

  Ali, Yaser M ^a   Kuriya, Bindee ^a   Orozco, Catalina ^b   Cush, John J ^b   Keystone, Edward C ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Fetal risk; Maternal risk; Pregnancy; Tumor necrosis factor inhibitor; Women

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

ADVERSE OUTCOME; ANKYLOSING SPONDYLITIS; ANUS ATRESIA; ARTHRITIS; BIRTH CONTROL; BIRTH DEFECT; BREAST FEEDING; CHROMOSOME ABERRATION; CLINICAL PRACTICE; CLINICAL STUDY; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CROHN DISEASE; CROSS REACTION; CRYPTORCHISM; DIGESTIVE SYSTEM MALFORMATION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG MEGADOSE; DRUG MILK LEVEL; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ENTERITIS; ESOPHAGUS ATRESIA; EYE MALFORMATION; FALLOT TETRALOGY; FETUS MALFORMATION; FETUS RISK; GENITAL MALFORMATION; GROWTH RETARDATION; HEART VENTRICLE SEPTUM DEFECT; HIP DYSPLASIA; HUMAN; HYDROCEPHALUS; IMMUNOTHERAPY; INTESTINE MALROTATION; JAW MALFORMATION; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY MALFORMATION; LACTATION; LIMB MALFORMATION; LIVE BIRTH; LOW BIRTH WEIGHT; MATERNAL HYPERTENSION; MICROCEPHALY; MUSCULOSKELETAL SYSTEM MALFORMATION; NERVOUS SYSTEM MALFORMATION; NONHUMAN; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREMATURITY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PYLORUS STENOSIS; REGISTER; REVIEW; RHEUMATOID ARTHRITIS; SPINA BIFIDA; SPONTANEOUS ABORTION; TERATOGENICITY; TERATOMA; TRACHEOESOPHAGEAL FISTULA; TRISOMY 18; TRISOMY 21; ULCERATIVE COLITIS; VERTEBRA MALFORMATION;

ABNORMALITIES, DRUG-INDUCED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FETUS; GUIDELINES AS TOPIC; HUMANS; LACTATION; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 73649087593     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090563     Document Type: Review

References (54)

1. Hench PS. The ameliorating effect of pregnancy on chronic atrophic (infectious rheumatoid) arthritis, fibrosis and intermittent hydrarthrosis. Mayo Clin Proc 1938;13:161.
2. Perselin RH. The effect of pregnancy on rheumatoid arthritis. Bull Rheum Dis 1976-77;27:922-7.
3. Nelson JL, Ostensen M. Pregnancy and rheumatoid arthritis. Rheum Dis Clin North Am 1997;23:195-212.
4. de Man YA, Dolhain RJ, van de Geijn FE, Willemsen SP, Hazes JMW. Disease activity of rheumatoid arthritis during pregnancy: Results from a nationwide prospective study. Arthritis Rheum 2008;59:1241-8.
5. Barrett JH, Brennan P, Fiddler M, Silman AJ. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum 1999;42: 1219-27.
6. Kaplan D, Diamond H. Rheumatoid arthritis and pregnancy. Clin Obstet Gynecol 1965;17:286-303.
7. Nelson JL, Koepsell TD, Dugowson CE, Voigt LF, Daling JR, Hansen JA. Fecundity before disease onset in women with rheumatoid arthritis. Arthritis Rheum 1993;36:7-14.
8. Nelson JL, Voigt LF, Koepsell TD, Dugowson CE, Daling JR. Pregnancy outcome in women with rheumatoid arthritis before disease onset. J Rheumatol 1992;19:18-21.
9. Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:899-907.
10. Chambers CD, Polifka JE, Friedman JM. Drug safety in pregnant women and their babies: ingnorance not bliss. Clin Pharmacol Ther 2008;83:181-3.
11. Lyerly AD, Mitchell LM, Armstrong EM, Harris LH, Kukla R, Kuppermann M, et al. Risks, values and decision making surrounding pregnancy. Obstet Gynecol 2007;109:979-84.
12. Scialli AR, Buelke-Sam JL, Chambers CD, Friedman JM, Kimmel CA, Polifka JE, et al. Communicating risks during pregnancy: a workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugs. Birth Defects Res A Clin Mol Teratol 2004;70:7-12.
13. US Food and Drug Administration. Pregnancy and lactation labeling. [Internet. Accessed October 22, 2009.] Available from: http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/Developm entResources/DrugInteractionsLabeling/ ucm093307.htm
14. IMS Intelligence Applied. http://www.imshealth.com/web/channel/
15. Treacy G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNF alpha monoclonal antibody. Hum Exp Toxicol 2000;19:226-8.
16. Briggs GG. Drugs in pregnancy and lactation. 7th ed. Baltimore: Williams and Wilkins; 2005.
17. European Medicines Agency. Scientific discussion. Humira. [Internet. Accessed October 22, 2009.] Available from: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/humira/ 400803en6.pdf
18. Strangfeld A. Pregnancy outcome after exposure to biologics: results from the German biologics register RABBIT [abstract]. Arthritis Rheum 2007;56 Suppl:S311.
19. Hyrich KL, Symmons DP, Watson KD, Silman AJ; British Society for Rheumatology Biologics Register. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum 2006;54:2701-2.
20. King YE, Watson KD, Symmons DPM, Hyrich KL, on behalf of the British Society for Rheumatology Biologics Register (BSRBR). Pregnancy outcome in women exposed to anti-TNF agents: An update from the British Society for Rheumatology Biologics Register (BSRBR) [abstract]. Arthritis Rheum 2008;58 Suppl:S542.
21. Joven BE, Garcia-Gonzales AJ, Ruiz T, et al. Pregnancy in women receiving anti TNF therapy. Experience in Spain [abstract]. Arthritis Rheum 2005;52 Suppl:S349.
22. Garcia J, Joven B, Ruiz T, et al. Pregnancy in women receiving anti TNF alpha therapy. Experience in Spain. Ann Rheum Dis 2006;65 Suppl 11:317.
23. Cush JJ. Biologic drug use: US perspectives on indications and monitoring. Ann Rheum Dis 2005;64 Suppl 4:iv18-23.
24. Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005;21:733-8.
25. Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Salzberg B, et al. Safety of infliximab in Crohn's disease: data from the 5000-patient TREAT registry. Gastroenterology 2004;126:A54.
26. Srinivasan R. Infliximab treatment and pregnancy outcome in active Crohn's disease. Am J Gastroenterol 2001;96:2274-5.
27. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99:2385-92.
28. Snoeckx Y, Keenan G, Sanders M, Gardiner M. Pregnancy outcomes in women taking infliximab: The infliximab safety database [abstract]. Arthritis Rheum 2008;58 Suppl:S426.
29. Chambers C, Johnson DL, Jones KL and the OTIS Collaborative Research Group. Pregnancy outcome in women exposed to anti-TNF-alpha medications: the OTIS Rheumatoid Arthritis in Pregnancy Study [abstract]. Arthritis Rheum 2004;50 Suppl:S479.
30. Johnson DL, Jones KL, Chambers C. The OTIS Collaborative Research Group. Pregnancy outcomes for Women exposed to etanercept: OTIS Autoimmune Diseases in Pregnancy Project [abstract]. Arthritis Rheum 2007 xxxx.
31. Chakravarty E, Sanchez-Yamamoto D, Bush T. The use of disease modifying antirheumatic drugs women with rheumatoid arthritis of childbearing age. A survey of practice patterns and pregnancy outcomes. J Rheumatol 2003;30:241-6.
32. Berthelot JM, De Bandt M, Goupille P, Solau-Gervais E, Lioté F, Goeb V, et al. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 2009;76:28-34.
33. Koskvik HS, Magnussen AM, Skomsvoll JF. One year follow-up of etanercept exposed pregnancies. Ann Rheum Dis 2005;64 Suppl III:449.
34. Johnson DL, Jones KL, Chambers C. The OTIS Collaborative Research Group. Pregnancy outcomes for women exposed to adalimumab: OTIS Autoimmune Diseases in Pregnancy Project. Presented at the European Crohn's and Colitis Organization (ECCO), Hamburg, Germany, February 2009.
35. Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut 2005;54:890.
36. Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig Dis Sci 2006;51:2045-7.
37. Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Inflamm Bowel Dis 2006;12:827-8.
38. Ventura SJ, Mosher WD, Curtin SC, Abma JC, Henshaw S. Highlights of trends in pregnancies and pregnancy rates by outcome: Estimates for the United States, 1976-96. Natl Vital Stat Rep 1999;47:1-9.
39. Hudson M, Flett G, Sinclair TS, Brunt PW, Templeton A, Mowat NA. Fertility and pregnancy in IBD. Int J Obstet Gynecol 1997;58:229-37.
40. Burt MJ, Frizelle FA, Barbezat GO. Pregnancy and exposure to infliximab. J Gastroenterol Hepatol 2003;18:465-6.
41. Kinder AJ, Edwards J, Samanta A, Nichol F. Pregnancy in rheumatoid arthritis patient on infliximab and methotrexate. Rheumatology 2004;43:1195-6.
42. Chambers CD, Johnson DL, Jones KL. Pregnancy outcome in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project. Presented at the European League Against Rheumatism Scientific Meeting, June 2007.
43. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor therapy. Rheumatology 2007;46:695-8.
44. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol 1997;50:1129-36.
45. Orozco C, Dao K, Cush JJ, Kavanaugh A. Safety of TNF inhibitors during pregnancy in patients with inflammatory arthritis [abstract]. Arthritis Rheum 2005;52 Suppl:S344.
46. Forger F. Infliximab in breast milk [abstract]. Lupus 2004;13:753.
47. Peltier M et al. Infliximab levels in breast-milk of a nursing Crohn's patient. Presented at the American College of Gastroenterology 66th Annual Scientific Meeting, Las Vegas, USA, October 2001.
48. Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 2009;43:613-6.
49. Ostensen M, Eigenmann GO. Etanercept in breast milk. J Rheumatol 2004;31:1017-8.
50. Stephens S, Brown DT, Nesbitt AM, Foulkes R. Lack of placental transfer and accumulation in milk of anti-TNF PEGylated Fab' fragments in rats [abstract]. Presented as an abstract at the European Cancer Conference, Barcelona, Spain, March 2007.
51. Carter JD, Valeriano J, Vasey FB. Tumor necrosis factor inhibition and VATER association: A causal relationship? J Rheumatol 2006;33:1014-7.
52. Johnson DL, Jones KL, Chambers C. The OTIS Collaborative Research Group. Pregnancy outcomes for women exposed to adalimumab: OTIS Autoimmune Diseases in Pregnancy Project [abstract]. Arthritis Rheum 2008;58 Suppl:S682.
53. Carter JD, Ladhani A, Ricca L, Valeriano J, Vasey FB. A safety assessment of TNF antagonists during pregnancy: A review of the FDA database. Arthritis Rheum 2007;56 Suppl:S286.
54. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: A review of the Food and Drug Administration database. J Rheumatol 2009;36:635-41.